Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 303

1.

Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution.

Glynn RJ, Lunt M, Rothman KJ, Poole C, Schneeweiss S, Stürmer T.

Pharmacoepidemiol Drug Saf. 2019 Aug 5. doi: 10.1002/pds.4846. [Epub ahead of print]

PMID:
31385394
2.

Male hypogonadism: 14-year prospective outcome in 550 men with type 2 diabetes.

Malipatil NS, Yadegarfar G, Lunt M, Keevil B, Siddals K, Livingston M, Roberts S, Narayanan P, Rutter M, Gibson JM, Donn R, Hackett G, Jones TH, Heald A.

Endocrinol Diabetes Metab. 2019 Mar 27;2(3):e00064. doi: 10.1002/edm2.64. eCollection 2019 Jul.

3.

Atmospheric HCFC-22, HFC-125, and HFC-152a at Cape Point, South Africa.

Kuyper B, Say D, Labuschagne C, Lesch T, Joubert WR, Martin D, Young D, Khan MAH, Rigby M, Ganesan AL, Lunt MF, O'Dowd C, Manning AJ, O'Doherty S, Davies-Coleman MT, Shallcross DE.

Environ Sci Technol. 2019 Aug 6;53(15):8967-8975. doi: 10.1021/acs.est.9b01612. Epub 2019 Jul 10.

PMID:
31251602
4.

General practice (GP) level analysis shows that patients' own perceptions of support within primary care as reported in the GP patient survey (GPPS) are as important as medication and services in improving glycaemic control.

Heald A, Stedman M, Lunt M, Livingston M, Cortes G, Gadsby R.

Prim Care Diabetes. 2019 May 24. pii: S1751-9918(18)30381-4. doi: 10.1016/j.pcd.2019.04.005. [Epub ahead of print]

PMID:
31133530
5.

Increase in CFC-11 emissions from eastern China based on atmospheric observations.

Rigby M, Park S, Saito T, Western LM, Redington AL, Fang X, Henne S, Manning AJ, Prinn RG, Dutton GS, Fraser PJ, Ganesan AL, Hall BD, Harth CM, Kim J, Kim KR, Krummel PB, Lee T, Li S, Liang Q, Lunt MF, Montzka SA, Mühle J, O'Doherty S, Park MK, Reimann S, Salameh PK, Simmonds P, Tunnicliffe RL, Weiss RF, Yokouchi Y, Young D.

Nature. 2019 May;569(7757):546-550. doi: 10.1038/s41586-019-1193-4. Epub 2019 May 22.

PMID:
31118523
6.

Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.

Pan Y, Norton S, Gwinnutt JM, Kearsley-Fleet L, Symmons DPM, Lunt M, Young A; BSRBR-RA Control Centre Consortium, Hyrich KL, Verstappen SMM.

PLoS One. 2019 May 20;14(5):e0215999. doi: 10.1371/journal.pone.0215999. eCollection 2019.

7.

Patient perception of support within primary care is as important as medication and services in achieving good glycaemic control.

Heald A, Stedman M, Lunt M, Cortes G, Livingston M, Gadsby R.

Int J Clin Pract. 2019 Jul;73(7):e13356. doi: 10.1111/ijcp.13356. No abstract available.

PMID:
31033111
8.

Effect of Timing and Duration of Statin Exposure on Risk of Hip or Knee Revision Arthroplasty: A Population-based Cohort Study.

Cook MJ, Sorial AK, Lunt M, Board TN, O'Neill TW.

J Rheumatol. 2019 Mar 15. pii: jrheum.180574. doi: 10.3899/jrheum.180574. [Epub ahead of print]

PMID:
30877207
9.

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.

Yiu ZZN, Mason KJ, Barker JNWN, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group.

Br J Dermatol. 2019 Mar 1. doi: 10.1111/bjd.17849. [Epub ahead of print]

10.

The costs of drug prescriptions for diabetes in the NHS.

Stedman M, Lunt M, Livingston M, Fryer AA, Moreno G, Bailey S, Gadsby R, Heald A.

Lancet. 2019 Jan 19;393(10168):226-227. doi: 10.1016/S0140-6736(18)33190-8. No abstract available.

PMID:
30663590
11.

Demographic factor clustering at a GP practice level in England and its relation to glycaemic outcomes: What we can learn from this.

Stedman M, Lunt M, Livingston M, Fryer A, Moreno G, Anderson S, Gadsby R, Heald A.

Int J Clin Pract. 2019 May;73(5):e13303. doi: 10.1111/ijcp.13303. No abstract available.

PMID:
30515926
12.

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2019 Apr;180(4):894-901. doi: 10.1111/bjd.17421. Epub 2019 Jan 15.

PMID:
30430546
13.

Assessment of global long interspersed nucleotide element-1 (LINE-1) DNA methylation in a longitudinal cohort of type 2 diabetes mellitus (T2DM) individuals.

Malipatil N, Lunt M, Narayanan RP, Siddals K, Cortés Moreno GY, Gibson MJ, Gu HF, Heald AH, Donn RP.

Int J Clin Pract. 2018 Oct 21:e13270. doi: 10.1111/ijcp.13270. [Epub ahead of print]

PMID:
30345607
14.

Developing a foot ulcer risk model: what is needed to do this in a real-world primary care setting?

Heald A, Lunt M, Rutter MK, Anderson SG, Cortes G, Edmonds M, Jude E, Boulton A, Dunn G.

Diabet Med. 2018 Oct 15. doi: 10.1111/dme.13837. [Epub ahead of print]

PMID:
30320946
15.

Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data.

Joseph RM, van Staa TP, Lunt M, Abrahamowicz M, Dixon WG.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):179-186. doi: 10.1002/pds.4649. Epub 2018 Sep 28.

16.

Real-world practice level data analysis confirms link between variability within Blood Glucose Monitoring Strip (BGMS) and glycosylated haemoglobin (HbA1c) in Type 1 Diabetes.

Heald AH, Livingston M, Fryer A, Cortes G, Anderson SG, Gadsby R, Laing I, Lunt M, Young RJ, Stedman M.

Int J Clin Pract. 2018 Dec;72(12):e13252. doi: 10.1111/ijcp.13252. Epub 2018 Aug 31.

PMID:
30168887
17.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

Br J Dermatol. 2019 Feb;180(2):329-337. doi: 10.1111/bjd.17036. Epub 2018 Oct 21.

PMID:
30070708
18.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, Isaacs JD, Hyrich KL; BSRBR-RA Contributors Group.

Ann Rheum Dis. 2018 Oct;77(10):1405-1412. doi: 10.1136/annrheumdis-2018-213378. Epub 2018 Jul 6.

19.

Psychosocial factors partially mediate the relationship between mechanical hyperalgesia and self-reported pain.

Mason KJ, O'Neill TW, Lunt M, Jones AKP, McBeth J.

Scand J Pain. 2018 Jan 26;18(1):59-69. doi: 10.1515/sjpain-2017-0109.

PMID:
29794289
20.

Responsiveness of Single versus Composite Measures of Pain in Knee Osteoarthritis.

Parkes MJ, Callaghan MJ, Tive L, Lunt M, Felson DT.

J Rheumatol. 2018 Aug;45(9):1308-1315. doi: 10.3899/jrheum.170928. Epub 2018 May 1.

21.

Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review.

Gwinnutt JM, Sharp CA, Symmons DPM, Lunt M, Verstappen SMM.

Semin Arthritis Rheum. 2018 Dec;48(3):384-398. doi: 10.1016/j.semarthrit.2018.03.004. Epub 2018 Mar 15.

22.

Assumptions made when preparing drug exposure data for analysis have an impact on results: An unreported step in pharmacoepidemiology studies.

Pye SR, Sheppard T, Joseph RM, Lunt M, Girard N, Haas JS, Bates DW, Buckeridge DL, van Staa TP, Tamblyn R, Dixon WG.

Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):781-788. doi: 10.1002/pds.4440. Epub 2018 Apr 17.

23.

Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Mason KJ, Barker JNWN, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group.

JAMA Dermatol. 2018 May 1;154(5):581-588. doi: 10.1001/jamadermatol.2018.0183.

24.

Long-term persistence with rituximab in patients with rheumatoid arthritis.

Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, Hyrich KL; BSRBR-RA Contributors Group.

Rheumatology (Oxford). 2018 Jun 1;57(6):1089-1096. doi: 10.1093/rheumatology/key036.

25.

Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.

Heald AH, Fryer AA, Anderson SG, Livingston M, Lunt M, Davies M, Moreno GYC, Gadsby R, Young RJ, Stedman M.

Diabetes Obes Metab. 2018 Jul;20(7):1659-1669. doi: 10.1111/dom.13281. Epub 2018 Apr 17.

PMID:
29516618
26.

Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM.

Ann Rheum Dis. 2018 Jun;77(6):848-854. doi: 10.1136/annrheumdis-2017-212426. Epub 2018 Feb 23.

27.

Quality of life, sleep and rheumatoid arthritis (QUASAR): a protocol for a prospective UK mHealth study to investigate the relationship between sleep and quality of life in adults with rheumatoid arthritis.

Druce KL, Cordingley L, Short V, Moore S, Hellman B, James B, Lunt M, Kyle SD, Dixon WG, McBeth J.

BMJ Open. 2018 Jan 26;8(1):e018752. doi: 10.1136/bmjopen-2017-018752.

28.

Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort.

Little J, Parker B, Lunt M, Hanly JG, Urowitz MB, Clarke AE, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Buyon J, Isenberg DA, Rahman A, Ginzler EM, Petri M, Dooley MA, Fortin P, Gladman DD, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Sam Lim S, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Sanchez-Guerrero J, Bruce IN.

Rheumatology (Oxford). 2018 Apr 1;57(4):677-687. doi: 10.1093/rheumatology/kex444.

29.

Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.

Herrick AL, Peytrignet S, Lunt M, Pan X, Hesselstrand R, Mouthon L, Silman AJ, Dinsdale G, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk MC, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jobanputra P, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov NS, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman SM, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2018 Apr;77(4):563-570. doi: 10.1136/annrheumdis-2017-211912. Epub 2018 Jan 6.

30.

Social deprivation modifies the association between incident foot ulceration and mortality in type 1 and type 2 diabetes: a longitudinal study of a primary-care cohort.

Anderson SG, Shoo H, Saluja S, Anderson CD, Khan A, Livingston M, Jude EB, Lunt M, Dunn G, Heald AH.

Diabetologia. 2018 Apr;61(4):959-967. doi: 10.1007/s00125-017-4522-x. Epub 2017 Dec 21.

31.

Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.

Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuta C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, Inanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Herrick AL.

Rheumatology (Oxford). 2018 Feb 1;57(2):370-381. doi: 10.1093/rheumatology/kex410.

32.

Reproductive Hormone Levels Predict Changes in Frailty Status in Community-Dwelling Older Men: European Male Ageing Study Prospective Data.

Swiecicka A, Eendebak RJAH, Lunt M, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Slowikowska-Hilczer J, Lean MEJ, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FCW, Rutter MK; European Male Ageing Study Group.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):701-709. doi: 10.1210/jc.2017-01172.

33.

The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.

Kitson SJ, Lindsay J, Sivalingam VN, Lunt M, Ryan NAJ, Edmondson RJ, Rutter MK, Crosbie EJ.

Gynecol Oncol. 2018 Jan;148(1):154-160. doi: 10.1016/j.ygyno.2017.11.019. Epub 2017 Nov 24.

34.

Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit.

Heald AH, Livingston M, Fryer A, Moreno GYC, Malipatil N, Gadsby R, Ollier W, Lunt M, Stedman M, Young RJ.

Diabet Med. 2018 Jan;35(1):63-71. doi: 10.1111/dme.13541.

PMID:
29120503
35.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group.

J Invest Dermatol. 2018 Apr;138(4):775-784. doi: 10.1016/j.jid.2017.09.044. Epub 2017 Dec 6.

36.

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group.

J Invest Dermatol. 2018 Mar;138(3):534-541. doi: 10.1016/j.jid.2017.10.005. Epub 2017 Oct 17.

37.

Atmospheric observations show accurate reporting and little growth in India's methane emissions.

Ganesan AL, Rigby M, Lunt MF, Parker RJ, Boesch H, Goulding N, Umezawa T, Zahn A, Chatterjee A, Prinn RG, Tiwari YK, van der Schoot M, Krummel PB.

Nat Commun. 2017 Oct 10;8(1):836. doi: 10.1038/s41467-017-00994-7.

38.

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Silva-Fernández L, De Cock D, Lunt M, Low AS, Watson KD; BSRBR-RA Contributors Group, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2018 Sep 1;57(9):1533-1540. doi: 10.1093/rheumatology/kex304.

39.

Reply.

Gwinnutt JM, Symmons DPM, Lunt M, Verstappen SMM.

Arthritis Rheumatol. 2017 Dec;69(12):2402-2403. doi: 10.1002/art.40311. Epub 2017 Nov 2. No abstract available.

40.

A comparison of methods for estimating the temporal change in a continuous variable: Example of HbA1c in patients with diabetes.

Sheppard T, Tamblyn R, Abrahamowicz M, Lunt M, Sperrin M, Dixon WG.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1474-1482. doi: 10.1002/pds.4273. Epub 2017 Aug 15.

41.

Nonandrogenic Anabolic Hormones Predict Risk of Frailty: European Male Ageing Study Prospective Data.

Swiecicka A, Lunt M, Ahern T, O'Neill TW, Bartfai G, Casanueva FF, Forti G, Giwercman A, Han TS, Lean MEJ, Pendleton N, Punab M, Slowikowska-Hilczer J, Vanderschueren D, Huhtaniemi IT, Wu FCW, Rutter MK; EMAS Study Group.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2798-2806. doi: 10.1210/jc.2017-00090.

42.

Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Lapraik C, Marshall T, Lunt M, Verstappen SMM.

Rheumatology (Oxford). 2017 Sep 1;56(9):1510-1517. doi: 10.1093/rheumatology/kex172.

43.

Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM.

Arthritis Rheumatol. 2017 Aug;69(8):1566-1575. doi: 10.1002/art.40090. Epub 2017 Jul 10.

44.

Role of atmospheric oxidation in recent methane growth.

Rigby M, Montzka SA, Prinn RG, White JWC, Young D, O'Doherty S, Lunt MF, Ganesan AL, Manning AJ, Simmonds PG, Salameh PK, Harth CM, Mühle J, Weiss RF, Fraser PJ, Steele LP, Krummel PB, McCulloch A, Park S.

Proc Natl Acad Sci U S A. 2017 May 23;114(21):5373-5377. doi: 10.1073/pnas.1616426114. Epub 2017 Apr 17.

45.

Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over.

Armbrecht G, Felsenberg D, Ganswindt M, Lunt M, Kaptoge SK, Abendroth K, Aroso Dias A, Bhalla AK, Cannata Andia J, Dequeker J, Eastell R, Hoszowski K, Lyritis G, Masaryk P, van Meurs J, Miazgowski T, Nuti R, Poór G, Redlund-Johnell I, Reid DM, Schatz H, Todd CJ, Woolf AD, Rivadeneira F, Javaid MK, Cooper C, Silman AJ, O'Neill TW, Reeve J; European Vertebral Osteoporosis Study and European Prospective Osteoporosis Study Groups.

Rheumatology (Oxford). 2017 Jul 1;56(7):1189-1199. doi: 10.1093/rheumatology/kex040.

46.

Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.

Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM.

Br J Dermatol. 2017 Nov;177(5):1410-1421. doi: 10.1111/bjd.15531. Epub 2017 Oct 19.

47.

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.

Humphreys JH, Warner A, Costello R, Lunt M, Verstappen SMM, Dixon WG.

Ann Rheum Dis. 2017 Sep;76(9):1509-1514. doi: 10.1136/annrheumdis-2016-210629. Epub 2017 Mar 23.

48.

Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).

Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, Brown E, Czirják L, Distler JHW, Distler O, Fligelstone K, Gregory WJ, Ochiel R, Vonk M, Ancuţa C, Ong VH, Farge D, Hudson M, Matucci-Cerinic M, Balbir-Gurman A, Midtvedt Ø, Jordan AC, Jobanputra P, Stevens W, Moinzadeh P, Hall FC, Agard C, Anderson ME, Diot E, Madhok R, Akil M, Buch MH, Chung L, Damjanov N, Gunawardena H, Lanyon P, Ahmad Y, Chakravarty K, Jacobsen S, MacGregor AJ, McHugh N, Müller-Ladner U, Riemekasten G, Becker M, Roddy J, Carreira PE, Fauchais AL, Hachulla E, Hamilton J, İnanç M, McLaren JS, van Laar JM, Pathare S, Proudman S, Rudin A, Sahhar J, Coppere B, Serratrice C, Sheeran T, Veale DJ, Grange C, Trad GS, Denton CP.

Ann Rheum Dis. 2017 Jul;76(7):1207-1218. doi: 10.1136/annrheumdis-2016-210503. Epub 2017 Feb 10.

49.

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K; BSRBR-RA*; BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL.

RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. Erratum in: RMD Open. 2017 Feb 23;3(1):e000314corr1.

50.

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.

Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium.

Ann Rheum Dis. 2017 Apr;76(4):654-660. doi: 10.1136/annrheumdis-2016-209784. Epub 2017 Jan 10.

Supplemental Content

Support Center